Asymmetric Synthesis of an Antagonist of Neurokinin Receptors: SSR 241586 | Zendy

ThomasXavier Métro | Zendy; Anne Cochi | Zendy; Domingo Gomez Pardo | Zendy; Janine Cossy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Asymmetric Synthesis of an Antagonist of Neurokinin Receptors: SSR 241586

Author(s) -

ThomasXavier Métro,

Anne Cochi,

Domingo Gomez Pardo,

Janine Cossy

Publication year - 2011

Publication title -

the journal of organic chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.2

H-Index - 228

eISSN - 1520-6904

pISSN - 0022-3263

DOI - 10.1021/jo102471r

Subject(s) - neurokinin b , tachykinin receptor , substance p , neurokinin a , bronchoconstriction , nk1 receptor antagonist , chemistry , antagonist , receptor , neurogenic inflammation , pharmacology , neuropeptide , irritable bowel syndrome , medicine , asthma , biochemistry

SSR 241586 is a 2,2-disubstituted morpholine, developed by Sanofi-Aventis, which is active in the treatment of schizophrenia and irritable bowel syndrome (IBS). Different strategies have been studied to synthesize this molecule and among the strategies an organo-catalyzed Henry reaction, applied to an α-keto ester, has produced SSR 241586 in excellent enantiomeric excess.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research